AHS Cancer Control Alberta
Many people develop joint pain, stiffness and swelling due to their cancer treatment that targets the immune system. The severity of symptoms ranges from mild to debilitating and sometimes requires delaying or stopping cancer treatment. The usual plan is to discontinue cancer treatment and give relatively high doses of a medication called prednisone (a steroid, which is an anti-inflammatory medication which may suppress the immune system) with a gradual lowering of the dose over several weeks. While this can be effective, prednisone can cause a number of side effects, and it is not known if this is the best or safest treatment. Hydroxychloroquine is a medication that is often used to treat inflammatory joint pain, such as rheumatoid arthritis, has relatively few side effects when compared to prednisone, and may be effective at treating this condition. The purpose of this study is to find out whether it is better to receive hydroxychloroquine and prednisone, or prednisone alone for joint pain. To do this, some participants will get hydroxychloroquine and some will receive a placebo (a substance that looks like the study drug but does not have any active or medicinal ingredients). A placebo is used to make the results of the study more reliable. This is a double-blinded study, which means that neither participants nor the study doctor or study staff will know which group participants are allocated. After 12 weeks of study treatment, the blind will be opened and participants will be informed which treatment was given.
Arthritis
Arthralgia
Hydroxychloroquine
Placebo
Phase 2
Study Type : | Interventional |
Estimated Enrollment : | 46 participants |
Masking : | Triple |
Primary Purpose : | Treatment |
Official Title : | A Study to Evaluate the Efficacy and Safety Hydroxychloroquine in Immune Related Arthritis or Arthralgias |
Actual Study Start Date : | September 16, 2021 |
Estimated Primary Completion Date : | July 2025 |
Estimated Study Completion Date : | July 2028 |
Arm | Intervention/treatment |
---|---|
Experimental: Hydroxychloroquine, plus prednisone Hydroxychloroquine 5mg/kg PO daily, plus prednisone starting at 20 mg PO daily for 8 weeks tapering dose. |
Drug: Hydroxychloroquine |
Placebo Comparator: Hydroxychloroquine-matching placebo, plus prednisone Matching placebo daily, plus prednisone starting at 20 mg PO daily for 8 weeks tapering dose. |
Other: Placebo |
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Recruiting
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2